Date: 21 March 2018 | Time: 16:57
Contract Research and Development Organisation Arcinova has announced a new collaboration with Sterling Pharma Solutions in a move that will significantly enhance the two companies’ service offerings to their global client bases.
Alnwick, UK-based Arcinova will now have access to Sterling Pharma Solutions’ scale up and pilot plant assets, which will complement the company’s existing facilities. Sterling Pharma Solutions is headquartered in Cramlington, UK and is just 28 miles from the Arcinova site.
The facilities include pilot plant assets ranging from 50lt up to 1300lt capacity, with 5-100kg batch generation capability. The combined service offering will allow Arcinova to ensure technical transfer from grams to 100’s kilogram scale and is designed to ensure an integrated facility to meet clients’ drug substance requirements, from preclinical through to full scale commercial launch phases.
The scale up process will be executed by trained Arcinova personnel, supported by the long-established skills, infrastructure and capacity of Sterling Pharma Solutions. Both organisations are very experienced in the provision of secure sources of supply for technically challenging projects.
Arcinova provides both integrated end to end solutions and standalone services to pharmaceutical and biotech companies. It works across drug substance synthesis, drug product manufacture, CMC, bioanalytical and metabolism services, radiolabelling synthesis and synthesis of toxic/highly potent Active Pharmaceutical Ingredients (APIs). It also provides consultancy services and works in partnership with companies throughout the drug development process.
Sterling Pharma Solutions is a world leading provider of small molecule API development and manufacturing services to the global pharmaceutical industry.
Ian Shott CBE, CEO of Arcinova and Investor/Director at Sterling Pharma Solutions said: “I’m delighted that Arcinova and Sterling Pharma Solutions have forged this partnership: by working in collaboration and combining expertise and specialist capabilities, we can offer an even wider ranging service to the global pharmaceutical and biotechnology communities and further strengthen the level of support we offer to our clients.”
Paul Quigley, head of API at Arcinova, said: “This new capability will ensure technical transfer from grams to 100’s kilogram scale – thanks to our collaboration with Sterling Pharma Solutions – which is a hugely exciting development for Arcinova and reflects the increased demand we have seen for our API services.
“In addition, this collaboration demonstrates the strength of North East England’s pharmaceutical sector and our ability to make an impact on a global scale.”
Kevin Cook, CEO at Sterling Pharma Solutions added: “This collaboration brings together complementary capabilities to make the North East of England the right choice for pharmaceutical development, scale-up and commercial manufacture.”
Launched in 2016, Arcinova operates from a 15,000m2 facility on a 34-acre site, which has benefited from decades of investment as a key research and development centre for Sanofi and Covance, allowing it to offer a unique range of complementary on-site capabilities as a Contract Research and Development Organisation (CRDO).
Arcinova’s senior scientific team are renowned for their world class, specialist research and development expertise and their big pharma and CRDO experience gives them extensive, broad ranging industry knowledge and insight.
Arcinova works with big pharma, specialty pharma and biotech companies across the globe, from established multinationals to emerging start-ups.
We are Horizonworks - the B2B marketing specialists focussed on working with B2B companies from strategy to delivery.Read more >
Our strategy-led approach underpins success and guides B2B companies on their marketing journey.Read more >
10 reasons why you should partner with Horizonworks - the B2B marketing specialists.Read more >